Radiofrequency endometrial ablation for treating heavy menstrual bleeding in women with chronic renal failure

Figures & data

Table 1. The demographic and clinical characteristics of the study cohort.

Demographic and clinical characteristics	Values
Age (years)	41.4 ± 7.7
Gravidity (n)	3.0 (0.0–10.0)
Parity (n)	1.0 (0.0–5.0)
Uterine polyps (n)	6
Adenomyosis (n)	2
Uterine septum (n)	2
Intrauterine adhesion (n)	3
Intermural fibroids (n)	3
Renal hypertension (n)	58
Secondary hyperparathyroidism (n)	7
Hypertensive cardiovascular disease (n)	6
Systemic lupus erythematosus (n)	3
Hemoglobin level (g/dL)	69.6 ± 19.3
Creatinine level (umol/L)	879.1 ± 415.4
Urea level (mmol/L)	18.2 ± 7.1
Uric acid (µmol/L)	429.6 ± 109.4

Figure 1. A hysteroscopic view of the endometrial cavity prior to (left) and after (right) NovaSure^® endometrial ablation.

Table 2. The results pertaining to the treatment of heavy menstrual bleeding in patients with chronic renal failure.

Variables	Values
Depth of the uterine cavity (cm)	5.2 ± 0.7
Width of the uterine cavity (cm)	4.2 ± 0.7
Power output (watts)	119.0 ± 27.0
Treatment time (s)	61.7 ± 18.8
Estimated blood loss (mL)	10.0 (2–50)
Length of hospital stay (days)	4.7 ± 2.4
Duration of follow-up (months)^a
6–12	18
13–24	10
25–36	17
37–48	9
>48	4
Bleeding pattern (n)
Amenorrhea	53
Spotting	4
Heavy menstrual bleeding	1

^a Mean follow-up duration (months) = 24.4 ± 14.9.